Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Conditions: Schizophrenia Agitation; Schizo Affective Disorder; Bipolar Disorder; Dexmedetomidine Interventions: Drug: Dexmedetomidine; Drug: Lorazepam 2 MG/ML Sponsors: Temple University; BioXcel Therapeutics Inc Recruiting

https://clinicaltrials.gov/study/NCT06093451

Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials